. The HIV-OL responsible for the greatest reduction in prevalence between the two periods was oral candidiasis, of which erythematous candidiasis was the clinical form that decreased most, followed by pseudomembranous candidiasis. In conclusion, we observed a significant reduction in HIV-OLs, which was closely associated with the use of ART. In addition, among patients with a clinical diagnosis of AIDS, we confirmed a significant reduction in
Introduction
Acquired immunodeficiency syndrome (AIDS) is a severe disease and is the late manifestation of human immunodeficiency virus (HIV) infection (1) (2) (3) . It has been estimated that 33.4 million people are infected by HIV worldwide (4) . In Brazil, 544,846 cases were reported from 1980 through 2009 and 217,091 deaths occurred between 1980 and 2008 (5) .
In 1986, the capacity of zidovudine (AZT) to inhibit HIV replication was discovered, and the Brazilian government authorized the free distribution of this drug in 1992 (6) . In 1996, the efficacy of antiretroviral therapy (ART) in treating HIV was proved. ART, which has been defined as the combination of two or three classes of drugs (7), reduced the number of deaths and significantly increased quality of life among people with AIDS (8, 9) . In 1996, the Brazilian government signed a law establishing the free distribution of AZT, which gave HIV-seropositive patients access to antiretroviral (ARV) drugs. Later, and particularly after 2001, the Brazilian government was able to markedly reduce the prices of ARV drugs by means of patent infringement. Such efforts further increased the distribution of these medicines by the public health network. The number of patients receiving free ARV drugs through the public health system was 55,600 in 1997, 73,000 in 1999, and approximately 105,000 in 2001 (7) .
In the Clinical Hospital of the School of Medicine of Ribeirão Preto, University of São Paulo, Brazil (CH-SMRP-USP), where this study was conducted, ARV drugs started to be freely and efficiently distributed in 1996. In that year, with the advent of ART, only those patients who were not having good results with one or two ARVs were switched to ART, whereas therapy was unchanged for patients who remained stable on a regimen of one or two ARV drugs. Gradually, the number of patients on ART increased and encompassed nearly all patients receiving ARVs by 2004.
Oral lesions are associated with HIV progression and were described in the first cases of HIV infection (10, 11) . HIV-associated oral lesions (HIV-OLs) result from reduced immunity among infected individuals, which permits the development of diseases deriving from opportunistic pathogens (12) . Sometimes they present as the initial manifestations of AIDS and can precede systemic diseases (13, 14) . HIV-OLs can also exacerbate systemic symptoms, such as weight loss and diarrhea, that are common among individuals with HIV (12, (15) (16) (17) (18) . Because many HIV-OLs are easily visualized and diagnosed on the basis of their clinical characteristics, they are excellent indicators of an individual's immune status and permit evaluation of the extent of immunologic involvement (18) (19) (20) (21) .
The objective of the present study was to compare the prevalence of HIV-OLs during two time periods at CH-SMRP-USP. The first period was 1997, when many of the patients followed at the CH-SMRP-USP received two kinds of ARV drugs and only the most severe cases received ART. The second period was 2004 through 2008, when all patients receiving ARV drugs were treated with ART.
Subjects and Methods
An epidemiologic study was performed during two time periods to determine the prevalence of HIV-OLs among HIV-seropositive patients that were followed-up at the CH-SMRP-USP. A total of 148 and 388 seropositive participants were examined in 1997 and 2004-2008, respectively, and the participants evaluated in [2004] [2005] [2006] [2007] [2008] were not necessarily those who were seen in 1997. The other inclusion criteria were age older than 18 years and data on recent T CD4 lymphocyte counts (CD4+L) 3 months before and 3 months after an oral exam.
The same methodology and same criteria for classification of HIV-OLs were used during both time periods. Evaluation of the participants comprised anamnesis, lymph node palpation, perioral examination, and oral examination. HIV-OLs were identified according to the criteria of the EC-Clearinghouse on Oral Problems Related to HIV Infection and the WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus, 1993 (22) . The protocols of these studies were previously approved by the Ethics Committee of CH-SMRP-USP, and all patients gave written informed consent to participate.
Treatment that included one or more antiretroviral agents including nucleosides but excluding protease inhibitors was defined as antiretroviral (ARV) drug treatment, and treatment that included one or more antiretroviral agents plus protease inhibitors was defined as ART.
The software packages GraphPad 3.01 (GraphPad Software Inc., San Diego, CA, USA) and GraphPad Prism 4.00 were used for the statistical analysis. Variables such as age, duration of seropositivity time, and CD4 + L count were analyzed using the Student t-test, and data normality was verified using histograms constructed 
Results
The relevant demographic and clinical characteristics of the seropositive patients, i.e., age, CD4 + L count, smoking status, and ARV use, differed between the two study periods; the ratio of men to women was similar ( Table 1 In 1997, patients who were not receiving ARV/ART had a lower prevalence of HIV-OLs than did those who were (P = 0.0011; Table 3 ). In 1997, 39/83 (47%) of patients not receiving ARV drugs developed HIV-OLs, whereas the prevalence of HIV-OLs was higher among patients receiving ART: 77.8% (14/18). We observed HIV-OLs in 76.6% (36/47) of patients receiving ARVs. (Table 4) .
Discussion
The prevalence of HIV-OLs differs by country. The AIDS epidemic has been discussed in relation to its medical context (15, (23) (24) (25) (26) (27) (28) and epidemiologic and socioeconomic characteristics (29) (30) (31) ; however, few studies have described the prevalence of HIV-OL in Brazil, especially with regard to changes in the prevalence of HIV-OL that occurred with the advent of ART era (32) .
Since 1992, and to a greater extent since 1996, the Ministry of Health has guaranteed free access to ARVs OR: odds ratio, CI: confidence interval, * statistically significant for people with AIDS living in Brazil (7, 33) . In 2001, the Brazilian government infringed patents to obtain a large reduction in the cost of ARVs, from US $303 million in 2000 to US $232 million in 2001 (7). ART, which began in 1996 after the discovery of new classes of ARVs, eg, protease inhibitors, was the beginning of a new phase in AIDS treatment. It radically changed the quality of life of seropositive patients, because treatment now controlled viral load while drastically decreasing the resistance of HIV to ARVs (34) .
In CH-SMRP-USP, the site of the present study, patients started to receive ARVs free of charge in 1996, which was the same year that some patients began ART. However, only patients who did not respond to the use of one or two ARVs received ART. Gradually, ART was provided to all patients who used ARVs. In 1997, most patients on ARVs received a combination of two nucleoside reverse transcriptase inhibitors (NRTIs)-comprising mainly AZT, dideoxyinosine (DDI), and dideoxycytidine (DDC). (35) (36) (37) (38) (39) . In 1997, HIV-OLs were present in patients receiving ARVs, probably because these drugs were mainly given to patients with complications of HIV infection and also because most patients were receiving ARVs rather than ART. Of the 65 participants receiving ARV therapy in 1997, 73% were receiving ARVs and only 27% were receiving ART. It is important to mention that the patients receiving ART were those who had not satisfactorily responded to ARVs. Thus, because ART was indicated mainly for the most severe cases, HIV-OLs were predominant in this group in 1997. (41) showed that OC was more prevalent among patients with a low CD4+L count and high viral loads.
We found no reduction in HL prevalence between the two study periods. HL prevalence was 12.8% in 1997 and In 1997, 65.4% of participants with a clinical diagnosis of AIDS developed HIV-OLs; in [2004] [2005] [2006] [2007] [2008] , this number decreased to 33.8% (P < 0.0001), which shows the efficacy of ART in decreasing the incidence of HIV-OLs, even among patients with HIV-related complications.
In summary, we observed a significant reduction in HIV-OLs, which was closely related to the use of ART. The oral lesion with the greatest decrease in prevalence was oral candidiasis, especially the erythematous and pseudomembranous forms. In addition, we observed a significant reduction in the prevalence of oral lesions in patients with a clinical diagnosis of AIDS.
